SEC Contract Filing

Filing Date: 2018-11-13

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>exh10-1.htm
<DESCRIPTION>STOCKHOLDERS AGREEMENT, DATED JULY 27, 2018, BY AND AMONG NALPROPION PHARMACEUTICALS, INC.,
<TEXT>
<!-- saved from url=(0022)http://internet.e-mail -->
<html>
<!-- Edgar-valid HTML by InstantEDGAR(TM) - Copyright Advanced Computer Innovations, Inc., 2014-2018 - Validation: OK -->
<head>
<title>.</title>
</head>
<body>
<div style=margin-left:72pt;width:468pt><p align=right style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt'><b>Exhibit 10.1</b></p>
<p align=justify style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt'>[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<hr style='border:0;height:0;width:0;margin:12pt 0 0 0'><p align=center style='font:10pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'><font style='font:10pt Times New Roman'><b>STOCKHOLDERS AGREEMENT</b></font></p>
<p style='font:12pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p style='font:12pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p align=center style='font:10pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'><font style='font:10pt Times New Roman'>among</font></p>
<p style='font:12pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p style='font:12pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p style='font:12pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p align=center style='font:10pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'><font style='font:10pt Times New Roman'><b>NALPROPION PHARMACEUTICALS, INC.</b></font></p>
<p style='font:12pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p style='font:12pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p style='font:12pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p align=center style='font:10pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'><font style='font:10pt Times New Roman'>and</font></p>
<p style='font:12pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p style='font:12pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p style='font:12pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p align=center style='font:10pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'><font style='font:10pt Times New Roman'><b>the Stockholders named herein</b></font></p>
<p style='font:12pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p style='font:12pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p align=center style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:10pt'><font style=font-size:10pt>dated as of</font></p>
<p style='font:12pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p align=center style='font:10pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'><font style='font:10pt Times New Roman'>July 27, 2018</font></p>
<hr style='border:0;height:0;width:0;margin:12pt 0 0 0'><p style='font:10pt Calibri;margin-top:0pt;margin-bottom:10pt;color:#000000'><font style='font:10pt Times New Roman'> </font>&nbsp;</p>
<hr style='page-break-after:always;border:0;height:3pt;background-color:#808080;margin:6pt 0'><p style=line-height:0;margin:0></p>
<p align=justify style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:12pt'>[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.</p>
<hr style='border:0;height:0;width:0;margin:12pt 0 0 0'><p align=center style='font:14pt Times New Roman;margin-top:0pt;margin-bottom:10pt'><font style=font-size:14pt><b>Stockholders Agreement</b></font></p>
<p align=justify style='font:12pt Calibri;margin-top:6pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p align=justify style='font:10pt Calibri;margin-top:6pt;margin-bottom:10pt;color:#000000'><kbd style=margin-left:36pt></kbd><font style='font:10pt Times New Roman'>This Stockholders Agreement (as amended, modified, supplemented or restated from time to time, this &#8220;<b>Agreement</b>&#8221;), dated as of July 27, 2018, is entered into by and among Nalpropion Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<b>Company</b>&#8221;), 1992 MSF International Ltd., 1992 Tactical Credit Master Fund, L.P., 1992 Master Fund Co-Invest SPC3 (collectively with 1992 MSF International Ltd. and 1992 Tactical Credit Master Fund, L.P., and each of their respective Permitted Transferees, the &#8220;<b>1992 Funds</b>&#8221;), Whitebox Caja Blanca Fund, LP, Whitebox Multi-Strategy Partners, L.P., Whitebox Asymmetric Partners, L.P. (collectively with Whitebox Caja Blanca Fund, LP and Whitebox Multi-Strategy Partners, L.P., and each of their respective Permitted Transferees, the &#8220;<b>Whitebox Funds</b>&#8221;), Pernix Ireland Pain Designated Activity Company (together with its Permitted Transferees, &#8220;<b>Pernix</b>&#8221;) and each other Person who after the date hereof acquires securities of the Company and agrees to become a party to, and bound by, this Agreement. The 1992 Funds, the Whitebox Funds, Pernix, and each other Person who after the date hereof acquires securities of the Company and agrees to become a party to, and bound by, this Agreement, in accordance with its terms and their respective Permitted Transferees, are each referred to herein as a &#8220;<b>Stockholder</b>&#8221; and, collectively, the &#8220;<b>Stockholders</b>&#8221;. </font>&nbsp;</p>
<p align=justify style='font:12pt Calibri;margin-top:6pt;margin-bottom:10pt;color:#000000'>&nbsp;</p>
<p align=center style='font:10pt Times New Ro